Pitavastatin plus Ezetemibe

ApprovedSmall molecule

Pitavastatin plus Ezetemibe is one of 67 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

HypertensionActive, not recruiting

DyslipidemiasRecruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

HypertensionApproved

Active, not recruiting

DyslipidemiasPreclinical

Recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Pitavastatin plus Ezetemibe

YYonsei University

Approved

1 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Apresoline

Novartis

Preclinical

7 5

Zebeta

Teva

Preclinical

6 6

Edarbi

Takeda

Preclinical

4 7

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 8

Winrevair

Alphagan

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Dyslipidemias

NCT05705804

Clinical

Trials by Indication[1]

Hypertension1 trial

Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents

Completed·YYonsei University·Phase 4·NCT01502904·120 enrolled

Dyslipidemias1 trial

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

Recruiting·YYonsei University·Preclinical·NCT05705804·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pitavastatin plus Ezetemibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pitavastatin plus Ezetemibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pitavastatin plus Ezetemibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYonsei University

Pitavastatin plus Ezetemibe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hypertension1 trial

Dyslipidemias1 trial

References

Drug Info

Quick Facts

Related News